Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication

Z Euler, G Alter - AIDS research and human retroviruses, 2015 - liebertpub.com
Z Euler, G Alter
AIDS research and human retroviruses, 2015liebertpub.com
The HIV field has seen an increased interest in novel cure strategies. In particular, new
latency reversal agents are in development to reverse latency to flush the virus out of its
hiding place. Combining these efforts with immunotherapeutic approaches may not only
drive the virus out of latency, but allow for the rapid elimination of these infected cells in a
“shock and kill” approach. Beyond cell-based approaches, growing interest lies in the
potential use of functionally enhanced “killer” monoclonal therapeutics to purge the …
Abstract
The HIV field has seen an increased interest in novel cure strategies. In particular, new latency reversal agents are in development to reverse latency to flush the virus out of its hiding place. Combining these efforts with immunotherapeutic approaches may not only drive the virus out of latency, but allow for the rapid elimination of these infected cells in a “shock and kill” approach. Beyond cell-based approaches, growing interest lies in the potential use of functionally enhanced “killer” monoclonal therapeutics to purge the reservoir. Here we discuss prospects for a monoclonal therapeutic-based “shock and kill” strategy that may lead to the permanent elimination of replication-competent virus, making a functional cure a reality for all patients afflicted with HIV worldwide.
Mary Ann Liebert